CD274 and bladder transitional cell carcinoma: Despite the increasing use of inhibitors targeting immune checkpoints such as PD-1 and PD-L1 in the treatment of BLCA, the efficacy of immunotherapy is still suboptimal, with a remission rate of about 25%35.